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health care system for methyl aminolevulinate (MAL)
PDT compared with a set of current treatment options.
METHODS: A decision-analytic approach was adopted
in which treatment pathways were deﬁned for both MAL
PDT and the current treatment options. The model
follows patients presenting with basal cell carcinoma
(BCC) or actinic keratosis (AK) through up to three lines
of treatment, accounting for the associated health care
costs. Epidemiological and GP referral/treatment para-
meters were determined from a survey of GPs. Treatment
modality and reconstructive surgery parameters were
determined from a survey of UK specialists familiar with
the treatment of NMSC. Further model parameters were
determined from an extensive literature review of the 
clinical data.
RESULTS: The surveys indicated that simple lesion 
excision is currently the favoured treatment modality 
for difﬁcult-to-treat BCC. For patients with difﬁcult-
to-treat AK, 5-ﬂuorouracil is currently the favoured 
treatment. In addition, the surveys showed that a large
number of patients undergoing lesion excision require
costly reconstructive surgery. The decision-analytic model
found MAL PDT had higher initial costs, but had cost-
offsets due to reduced requirement for reconstructive
surgery.
CONCLUSIONS: Higher initial costs associated with
MAL PDT are offset by savings from reduced recon-
structive surgery. Improved cosmetic outcome and
reduced need for surgery are also likely to impact on
patients’ treatment preferences and on quality of life.
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OBJECTIVE: Describe the utilization and costs of topical
corticosteroids (TCS) and physician visits in patients 
with atopic dermatitis (AD) from the third party payer
perspective.
METHODS: Data were extracted from Medstat’s 
MarketScan, a proprietary claims database, which
includes people who received pharmacy and medical ben-
eﬁts from various managed care organizations (MCOs).
We identiﬁed patients with continuous pharmacy cover-
age throughout 1999 with at least one ICD-9 code for
AD (691.8 or 692.9). TCS utilization was assessed as the
average number of prescriptions, average number of 
prescriptions per patient, and average quantity dispensed.
Drug costs are reported as the average AWP and average
MCO payment. All drug information was stratiﬁed by
brand/generic status. Physician visits were identiﬁed 
as either generalist or specialist. Costs for physician 
visits were identiﬁed from the 1999 PMIC physician fee
schedule.
RESULTS: 71,025 people were identiﬁed with AD, and
the estimated overall prevalence was 3.22%, and 3.93%
for patients 18 years of age or younger. Of these patients,
12.9% were treated with brand name TCS, at 1.5 pre-
scriptions (42 grams each) per patient per year (pppy),
and 12.9% were treated with generic TCS, at 1.5 pre-
scriptions (64 grams each) pppy. Brand name TCS 
prescribed to those £18 had an average AWP of $34.46
and an average MCO payment of $21.36. The corre-
sponding ﬁgures for generic TCS were $17.62 and
$10.09. Total MCO payments for TCS were $3.65 per
AD patient for 1999. Patients £18 years visited a gener-
alist approximately 1.2 times per year and specialist 1.4
times per year. Total physician visit costs were estimated
to be $172.60 per patient in 1999.
CONCLUSIONS: Despite the availability of generic TCS,
50% of prescriptions were for brand name products.
However, overall, TCS costs are small relative to the costs
for physician visits.
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Informal caregivers are individuals who provided uncom-
pensated care for their families and/or friends.
OBJECTIVES: To examine the impacts of visual impair-
ment (VI) on costs associated with informal caregivers in
the U.S. elderly population.
METHODS: We used data from the “Helper” ﬁle in 
the Asset and Health Dynamics Among the Oldest Old
(AHEAD) Wave I, a biennial prospective panel data 
collected for noninstitutionalized persons aged 70 years
old and over between 1993 and 1994. Time spent by the
informal caregivers (e.g., frequency of care per week,
hours spent per day) was combined with hourly wage
rates to calculate costs associated with informal care. VI
was approximated by those who reported poor eyesight
or legally blind in a self-reported health condition ques-
tion. Multivariate regression models were used to evalu-
ate the impacts of VI on informal care-givers’ costs while
accounting for confounding factors such as demograph-
ics and comorbidities.
RESULTS: Use of informal caregivers was found in
64.2% of the visually impaired group, almost three times
that of the visually unimpaired group (22.88%). On
average, the visually impaired group received 20.5 hours
of care weekly from informal caregivers, compared with
a weekly average of 5.3 hours in the visually unimpaired
group. The estimated monthly cost associated with 
informal caregivers was $980 for the visually impaired
and $253 for the visually unimpaired. Using the loga-
rithm of monthly costs as the dependent variable, the
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multivariate regression analysis showed that after 
controlling for demographics, geographic regions, and
comorbidities, the average cost of informal caregivers 
for the visually impaired was almost four times as high
as that of the visually unimpaired.
CONCLUSIONS: Our study indicated that the marginal
effect of VI on costs of informal care was higher than
many other health problems commonly seen in the
elderly, such as diabetes, arthritis, urinary incontinence,
etc.
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OBJECTIVE: Retrospective analysis of administrative
claims data was performed to evaluate impact of a single
course of isotretinoin therapy on direct cost of medical
treatment for severe recalcitrant nodular acne (SRNA).
Results were compared with projections of annual cost of
conventional therapy (excluding isotretinoin). Data and
METHODS: Using the MEDSTAT Marketscan database,
we identiﬁed 475 subjects aged 12–35 who received a
single course of isotretinoin lasting 90 days or longer
from 1995–1998. Acne-related expenditures were 
calculated during isotretinoin treatment and for periods
of 12 months pre and post-isotretinoin. Direct costs
(isotretinoin, systemic/topical antibiotics, laboratory
tests, and doctor ofﬁce visits) were examined, relative 
to individual subject characteristics (gender, age, health
plan). Applying a published methodology, projections of
annual cost of conventional therapy were made by costing
an algorithm for treatment, including antibiotic and
topical therapies (Bergfeld et al., J Am Acad Dermatol
1995;32 (suppl):S52–S56).
RESULTS: On average, subjects received isotretinoin for
141 days at cost of $1231. Mean total acne-related
expenses declined from $471 (median, $311) per year
prior to isotretinoin therapy to $135 (median, $48) per
year after treatment (p < .01). More than 25% of 
subjects had no acne-related expenditures for at least 12
months post-isotretinoin. Using projections for annual
cost of conventional therapies, average total therapy-
related expenditure for isotretinoin course ($1543, year
2000 dollars) would be recouped in 8 months for treat-
ment of minocycline + topical tretinoin; with shorter time
to recoup cost with branded medications. Projections for
combination therapy of topcial tretinoin + either oral 
erythromycin or tetracycline, indicated that isotretinoin
expenditure would be recouped in 1.9 to 2.3 years.
CONCLUSION: Isotretinoin therapy substantially
reduces total acne-related direct medical expenditures 
and may result in substantial cost savings. In addition,
the comparison of expense for isotretinoin therapy with
the estimated annual cost of long-term conventional 
treatment demonstrates an opportunity for substantial
healthcare savings in the treatment of SRNA.
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OBJECTIVES: Age related macular degeneration (AMD)
is the leading cause of blindness in the United Kingdom
and the rest of the western world, occurring in 15% to
30% of those over 75 years of age. About 15% of these
patients develop a more aggressive wet form of the disease
that causes severe loss of vision.
METHODS: Costs considered are those for treatment
and social care for people with low vision. The beneﬁt
estimates come from a 2-year clinical trial of 609 patients
that compared PDT with verteporﬁn to placebo. A
Markov model was used to extrapolate the results of 
the trial to a 5-year time horizon. Transition rates in 
the model were based on a time-to-event analysis using a
Weibull parametric hazard, with the assumption that the
treated eye is the better seeing eye. Two outcomes were
measured, vision years gained and quality adjusted life
years (QALYs) gained.
RESULTS: The cost per vision year gained estimates
range from £13,000 to £15,000 over 2 years, while those
modeled to 5 years range from £5,000 to £9,000. The
cost per QALY gained within the trial time frame range
from £58,000 to £66,000, and is estimated to range from
£22,000 to £43,000 at 5 years. Earlier intervention has
greater expected cost effectiveness in the long term, in
spite of more treatments being given overall. For example,
with a 5-year follow-up, starting a treatment cohort 
at 20/40 yields an expected cost per QALY of £22,000–
£30,000, but starting a cohort at 20/100 yields an
expected cost per QALY of £34,000–£43,000. The main
driver in the costs for the treatment group is the cost of
therapy, and these costs are estimated to occur mainly in
the ﬁrst 2 years.
CONCLUSION: Early intervention may yield acceptable
cost-effectiveness levels. Consideration should be given to
early detection and treatment of people with AMD.
